The abstract is read at the publisher; the summary is JClub's.
MGMT promoter methylation predicts progression-free and overall survival in glioblastoma treated with temozolomide, with hazard ratios of 2.07 and 2.13 using methylation-specific PCR and pyrosequencing.
- Why it matters: Current MGMT biomarker assessment has limited predictive accuracy due to an intermediate gray zone and variability across methylation assays and MGMT protein testing cut-offs.
- What they did: A systematic review and meta-analysis of 33 independent glioblastoma cohorts (4,691 patients) compared prognostic performance of MGMT promoter methylation versus MGMT protein expression, including methylation-specific PCR, pyrosequencing, and immunohistochemistry.
- The result: Methylation-specific PCR and pyrosequencing showed stronger prognostic value than immunohistochemical MGMT protein expression (HR 1.50), and methylation–protein inverse correlation appeared in 52% of studies, supporting independent prognostic contributions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.